Latent autoimmune diabetes in adults (LADA) - More than a name

Diabetologia

Volumn 49, Issue 9, 2006, Pages 1996-1998

  Groop, L ^a,b   Tuomi, T ^b   Rowley, M ^c   Zimmet, P ^d   Mackay, I R ^c  

^a LUND UNIVERSITY   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c MONASH UNIVERSITY   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY;

AUTOIMMUNE DISEASE; CELL FUNCTION; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; NOTE; PANCREAS ISLET BETA CELL; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOTHERAPY; INSULIN;

EID: 33746718136     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0345-x     Document Type: Note

References (19)

1. Gale EAM (2005) Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 48:2195-2199
2. Tuomi T, Groop L, Zimmet P, Rowley M, Mackay I (1993) Antibodies to glutamic acid decarboxylase (GAD) reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362
3. Groop L, Bottazzo GF, Doniach D (1986) Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 35:237-241
4. Groop L, Eriksson J, Ekstrand A et al (1991) Metabolic characteristics of autoimmune diabetes in adults. Diabetologia 34:46-51
5. Fourlanos S, Dotta F, Greenbaum CJ et al (2005) Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48:2206-2212
6. Tuomi T, Carlsson ÅL, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157
7. Dawkins RL (1985) Sensitivity and specificity of antibody testing. In: Rose NR, Mackay IR (eds) The autoimmune diseases. Academic, San Diego, pp 669-693
8. Mackay IR, Burnet FM (1963) Autoimmunity in thyroid disease. In: Autoimmune diseases. Pathogenesis, chemistry and therapy. Thomas, Springfield, pp 47-68
9. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM (2005) Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 54 (Suppl 2):S62-S67
10. Davis TME, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695-702
11. Scadding JG (1996) Essentialism and nominalism in medicine: logic of diagnosis in disease terminology. Lancet 348:594-596
12. Groop L, Miettinen A, Groop P-H et al (1988) Organ-specific autoimmunity and HLA-DR antigens as markers for β-cell destruction in patients with type II diabetes. Diabetes 37:99-103
13. Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
14. Florez JC, Burtt N, de Bakker PI et al (2004) Haplotype structure and genotype-phenotype correlations of the sulfonyulrea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 53:1360-1368
15. Grant SF, Thorleifsson, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320-323
16. Borg H, Gottsäter A, Fernlund P, Sundkvist G (1994) A 12-year prospective of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult onset diabetes. Diabetes 51:1754-1762
17. Tripathy D, Carlsson ÅL, Lehto M et al (2000) Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 43:1476-1483
18. Isomaa B, Almgren P, Henricsson M et al (1999) Chronic complications in patients with slowly progressing type 1 diabetes (LADA). Diabetes Care 22:1347-1353
19. Agardh CD, Cilio CM, Lethagen ÅL et al (2005) Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19:238-246